Abdin Alaa Din, Suffo Shady, Bischoff-Jung Mona, Daas Loay, Pattmöller Max, Seitz Berthold
Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, 66421, Homburg/Saar, Deutschland.
Ophthalmologe. 2020 Jan;117(1):50-57. doi: 10.1007/s00347-019-0911-5.
Since 2016, a designated center for the intravitreal injections (IVI) has been established at the department of ophthalmology. Many aims had supported the project of moving IVIs from the main operations theater. This study aimed to assess the practicality and feasibility of such a move.
In this IVI center, only patients with macular diseases are treated. The premises are arranged directly next to each other. The standardized treatment process starts with registration. Parallel to the formalities, a refraction test is carried out. If necessary optical coherence tomography (OCT) is carried out and then a full eye examination is performed by a doctor. Afterwards, a specialist/consultant decides on the subsequent treatment strategy. The injection takes place in an adjacent standard designated operating room. Patients are handed the computer-generated discharge letters immediately after the procedure and further appointments are booked on discharge.
Despite a 25% increase in the number of IVIs to more than 4000 IVIs per year over the last 2 years, advantages from the establishment of the designated center have resulted as follows: optimal care through precise treatment systems and shorter waiting times. From July to August 2018, 85% of voluntarily participating patients pressed the green or light green smiley face on the "HappyOrNot smiley terminal system". Pressure is taken off the regular outpatient macular consultation service, fixed and direct contact person, pressure is taken off the main operations theater with a significant increase in the diagnosis-related groups (DRG) revenues of 900,000 € and easily accessible database for statistical and scientific purposes.
The designated center proved to be an extremely useful and beneficial one-stop center (IVI carrousel) for patients requiring IVI and macular consultations. It significantly released the pressure on both the outpatient department and the outpatient operation center.
自2016年起，眼科设立了玻璃体内注射（IVI）指定中心。将玻璃体内注射从主手术室移出这一项目有诸多目标支持。本研究旨在评估此举的实用性和可行性。
在这个玻璃体内注射中心，仅治疗黄斑疾病患者。各区域彼此紧邻。标准化治疗流程始于登记。在办理手续的同时，进行验光测试。如有必要，进行光学相干断层扫描（OCT），然后由医生进行全面眼部检查。之后，由专科医生/顾问决定后续治疗策略。注射在相邻的标准指定手术室进行。术后立即将电脑生成的出院信交给患者，并在出院时预约后续就诊。
尽管在过去两年中玻璃体内注射数量增加了25%，每年超过4000次，但设立指定中心带来了以下优势：通过精确的治疗系统实现最佳护理，以及缩短等待时间。在2018年7月至8月期间，85%自愿参与的患者在“快乐与否笑脸终端系统”上按下了绿色或浅绿色笑脸。常规门诊黄斑咨询服务压力减轻，有固定且直接的联系人，主手术室压力减轻，诊断相关组（DRG）收入显著增加90万欧元，还有便于统计和科研的数据库。
该指定中心被证明是一个对需要玻璃体内注射和黄斑咨询的患者极为有用且有益的一站式中心（玻璃体内注射旋转木马）。它显著减轻了门诊部和门诊手术中心的压力。
